Brief: Medipost's Cartistem® Meets All Primary And Secondary Endpoints In Japan Phase 3 Trial And Demonstrates Statistically Significant Efficacy Gains Versus Active Control
14/05/2026 13:11
May 14 (Reuters) - Medipost Co Ltd 078160.KQ: MEDIPOST'S CARTISTEM® MEETS ALL PRIMARY AND SECONDARY ENDPOINTS IN JAPAN PHASE 3 TRIAL AND DEMONSTRATES STATISTICALLY SIGNIFICANT EFFICACY GAINS VERSUS ACTIVE CONTROL MEDIPOST CO LTD - JAPAN BIOLOGICS LICENSE APPLICATION FOR CARTISTEM SCHEDULED FOR 2H 2026 MEDIPOST CO LTD - CARTISTEM MAINTAINS EXCELLENT SAFETY PROFILE IN JAPAN PHASE 3 TRIAL MEDIPOST CO LTD - TO SUBMIT JAPAN MARKETING AUTHORIZATION APPLICATION IN 2026, TARGETS REGULATORY APPROVAL BY END 2027 MEDIPOST CO LTD - CARTISTEM ACHIEVES STATISTICAL SIGNIFICANCE VERSUS STANDARD-OF-CARE IN 52-WEEK JAPAN STUDY Source text: ID:nPn5dHTwca Further company coverage: 078160.KQ ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medipost Co
See all newsBrief: Medipost's Cartistem® Meets All Primary And Secondary Endpoints In Japan Phase 3 Trial And Demonstrates Statistically Significant Efficacy Gains Versus Active Control
Brief: Medipost Inc. Submits Ind Amendment With U.S. Food And Drug Administration To Initiate Phase Iii Trial
Brief: Medipost Co Q3 Operating Profit 2 Billion Won, Swings To Profit From Year Earlier
Brief: Medipost To Conduct Capital Increase Of 120 Billion Won
Brief: Medipost Co To Acquire 46 Billion Won Worth Of Shares In Unit Medipost America